Evidence map›Paper›PMID 41929055›Full record

ArticlebioRxiv : the preprint server for biology2026

Spatially-resolved single cell atlas of liposarcoma reveals lineage hierarchies, immune niches, and regulatory circuits.

Ryan A Denu, Veena Kochat, Zhao Zheng, Suresh Satpati, Danh D Truong, Emre Arslan, Corey Weistuch, Margarita Divenko, Manrong Wu, William Padron and 21 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Ryan A DenuDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-9698-9201
Veena KochatDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Zhao ZhengDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Suresh SatpatiDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Danh D TruongDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-3200-1297
Emre ArslanDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Corey WeistuchMemorial Sloan Kettering Cancer Center, New York, NY.
Margarita DivenkoDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Manrong WuDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
William PadronDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Davis R IngramDepartment of Pathology, Division of Pathology & Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Khalida M WaniDepartment of Pathology, Division of Pathology & Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Wei-Lien WangDepartment of Pathology, Division of Pathology & Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sharon M LandersDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hannah C BeirdDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jamie L McCuistoEpiCypher, Durham, NC.ORCID 0009-0000-6450-1590
Alysha SimmonsEpiCypher, Durham, NC.ORCID 0000-0002-5621-7298
Liz Marie Albertorio-SáezEpiCypher, Durham, NC.ORCID 0000-0003-3419-5849
Danielle N MaryanskiEpiCypher, Durham, NC.ORCID 0009-0002-9062-0520
Cheryl C SzanyEpiCypher, Durham, NC.ORCID 0009-0003-6013-9653
Bryan J VentersEpiCypher, Durham, NC.ORCID 0000-0002-4607-0587
Carolina Lin WindhamEpiCypher, Durham, NC.ORCID 0009-0004-7540-8390
Michael-Christopher KeoghEpiCypher, Durham, NC.ORCID 0000-0002-2219-8623
Keila E TorresDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Christina L RolandDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Emily Z KeungDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Elise F Nassif HaddadDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Alexander J LazarDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Joseph A LudwigDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Neeta SomaiahDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Kunal RaiDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
TRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8M
NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA009666
6 · The paper itself

Abstract

Well-differentiated and dedifferentiated liposarcoma (WDLPS and DDLPS) exhibit markedly different clinical behaviors, with DDLPS showing greater aggressiveness, higher recurrence and metastasis rates, and worse outcomes. Using single-nucleus multiome sequencing, epigenomic profiling, and spatial transcriptomics, we characterized cellular and epigenetic heterogeneity between these subtypes at single-cell and spatial resolution. We found distinct phenotypic states reflecting altered lineage differentiation and plasticity: DDLPS is dominated by early-differentiated progenitor-like cells, sclerotic WDLPS displays broader mesenchymal lineage plasticity, and adipocytic WDLPS contains abundant committed adipocytes. The DDLPS immune microenvironment was dominated by immunosuppressive macrophages, whereas WDLPS harbored more T cells and inflammatory macrophages. Notably, sclerotic WDLPS displayed intermediate cellular and molecular features, suggesting it may represent a distinct WDLPS subtype. Importantly, we identified novel gene regulatory circuits underlying each state, including FABP4/PPARG programs in adipocytic WDLPS, GLI2/TCF7L2/RBPJ/KLF7 programs in sclerotic WDLPS, and KLF7/FOSL2/SP3/GLI2/RBPJ programs in DDLPS. H3K27ac-marked enhancers were enriched near adipocytic marker genes in WDLPS and mesenchymal markers in DDLPS. Together, these findings reveal the cellular heterogeneity of tumor and immune compartments across liposarcoma subtypes and identify regulatory programs driving their differentiation states.

Identifiers

PMID41929055
PMCPMC13041956

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.